Lovastatin Tablet
Product Images NDC 68001-314

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 68001-314). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lovastatin 10mg 100ct Label (Image 01)

This appears to be a partial label for medication called Lovastatin, manufactured by Lupin Limited. The label includes the National Drug Code, dosage instructions, and storage information. The tablets come in child-resistant packaging and are intended for prescription use. The label warns to protect the medication from light and temperature extremes. However, the text is difficult to read due to errors from .*

FDA Label Image

Lovastatin 20mg 100ct Label (Image 02)

This text describes a container containing 100 tablets of Lovastatin (Tovastatin USP) 20 mg each, manufactured by Suebont Laboratories with a child-resistant closure at room temperature and protected from light. The package insert provides complete prescribing information. The NDC is 68001-315-00, and the tablets come in an unvarnished area.*

FDA Label Image

Lovastatin 40mg 100ct Label (Image 03)

This is a description of Lovastatin Tablets USP, a medication used to reduce high cholesterol levels. It comes in a pack of 100 tablets and each tablet contains 40mg of Lovastatin. The containers should be stored at controlled room temperature, protected from light and in a tight, light-resistant container. The usual dosage should be determined by a healthcare professional and the package insert should be consulted for complete prescribing information. The manufacturer is Lupin Limited.*

FDA Label Image

Lovastatin (Lovastatintabusp Figure 01)

FDA Label Image

Figure 1 (Lovastatintabusp Figure 02)

The text describes a figure with the title "Acute Major Coronary Events" and a primary endpoint. The figure shows a reduction in risk percentage of 87% with a statistical significance of p<0009 in the proportion of participants without an event. The x-axis of the figure represents years of follow-up.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.